Deceq 50 mg Powder for concentrate for solution for infusion
PDF Leaflet Revision Date: 12 December 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients (u2265 65 years) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML).
Dosage (summary)
20 mg/mu00b2 IV infusion over 1 hour for 5 consecutive days, repeated every 4 weeks.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic in animal studies.
Key Drug Interactions
- Caution with other medicines activated by phosphorylation or metabolized by cytidine deaminase.
Contraindications
- Hypersensitivity to decitabine
- Breastfeeding
Common side effects
- Myelosuppression
- Infections
- Febrile neutropenia
- Nausea
- Vomiting
Counselling Points
- Use effective contraception during treatment
- Monitor for signs of infection
- Avoid skin contact with solution
Serious warnings
- Risk of severe infections
- Myelosuppression complications
- Interstitial lung disease
Important Disclaimer
The Deceq 50 mg Powder for concentrate for solution for infusion professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
